Adagrasib is the first generation targeted drug

Adagrasib (Adagrasib) is a targeted drug. It is a KRAS G12C inhibitor specifically designed to treat cancer patients with KRAS G12C mutations. KRAS gene mutations are common in many different types of cancer, including non-small cell lung cancer, colorectal cancer, and other tumors. This mutation results in the production of an altered protein that triggers uncontrolled growth of cancer cells. Adagrasib works by inhibiting the activity of the KRAS G12C mutant gene, thereby interfering with the growth and spread of cancer cells.

Because adagrasib is a targeted drug, it acts more selectively on specific mutated genes present in cancer cells and will affect normal cells less than traditional chemotherapy drugs. This allows adagrasib to provide more effective treatment and reduce many of the side effects associated with traditional chemotherapy. Further clinical trial data point to the benefits of adagrasib for patients with non-small cell lung cancer. One major benefit is its safety, another benefit is its mode of administration (oral tablets). It is thought to offer patients an advantage over intravenous infusion of docetaxel, the standard of care for second-line treatment of advanced non-small cell lung cancer.

AdagrasibThe original drug has not yet been launched in China, and patients can only purchase adagrasib through overseas channels. The specifications of the original version in the United StatesThe price of 200mg*180 tablets per box is more than 100,000 yuan (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. For more drug information and specific prices, please consult Yaode’s medical consultant.